Amgen says Lumakras cuts risk of lung cancer progression by 34%
By Deena Beasley (Reuters) – Amgen Inc’s Lumakras pill reduced the risk of disease progression in patients with advanced lung cancer by 34% compared with …
progression
J&J, AbbVie cancer drug significantly slows progression of rare lymphoma: study
By Michael Erman (Reuters) – Johnson & Johnson and AbbVie’s big-selling leukemia drug Imbruvica in combination with standard treatment kept a rare type of non-Hodgkin …